5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib
- Resource Type
- Article
- Authors
- Asfaha, Yodita; Bollmann, Lukas M.; Skerhut, Alexander J.; Fischer, Fabian; Horstick, Nadine; Roth, Dennis; Wecker, Maria; Mammen, Christian; Smits, Sander H.J.; Fluegen, Georg; Kassack, Matthias U.; Kurz, Thomas
- Source
- In European Journal of Medicinal Chemistry 5 January 2024 263
- Subject
- Language
- ISSN
- 0223-5234